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OBJECTIVES: Under current economic and financial framework, some important
revisions were made to the National Pharmaceutical Policy in Portugal, aimed at
decreasing prices and contributing to lower public expenditure in the Health Sec-
tor. The Decree-Law 112/2011 introduced a new margin system both for pharma-
cies and wholesalers. A linear margin scheme, expressed as a percentage mark-up
on the consumer price before VAT was thus replaced by a regressive system com-
bining: i) a fixed fee that increases with the ex-factory price of drugs; ii) a regressive
margin expressed as a percentage of the ex-factory price. This paper aims to assess:
costs associated to the pharmacy dispensing and other pharmacy services pro-
vided; the proportion of purchased medicines on total prescribed; the perception of
pharmacists and patients regarding changes in access to medicines, namely pos-
sible shortages of medicines in Portuguese pharmacies, and other issues.
METHODS: In order to access the effects of this policy measure, surveys were
carried out to consumers and pharmacies across the country. Four surveys were
administered in week 25 to 29 June: survey to Pharmacy Owner; survey following
each prescription sale (one day census); survey about pharmacy services not asso-
ciated to the dispensing of medicines (5-day census). Pharmacists were also re-
quested to administer a survey to patients presenting a prescription. RESULTS: To
be completed after analysis of the surveys (after 29 June) CONCLUSIONS: We will
elaborate on a more efficient distribution of medicines in view of both the eco-
nomic sustainability of pharmacies and the impact on patients.
HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based
Agreements
PHP186
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OBJECTIVES: To explore opinions among professionals in health economics and
related fields on global trends in the use of health economic (HE) data in various
market access decision-making processes. METHODS: An on-line survey was ad-
ministered to professionals who work with HE data. The survey captured profes-
sional background characteristics and respondents’ opinions on trends in the role
of HE data in various decision-making areas and specifically in applying HE analy-
sis to individualized medicine and orphan medications. RESULTS: Seventy three
professionals completed the survey; 53% from Europe, 30% United States, and 16%
from other countries. 25% were from the pharmaceutical/medical technology in-
dustry, while 75% were from academia/government and other institution types.
The area where most respondents expected an increasing role for HE data was in
reimbursement decisions (89%), followed by manufacturers’ internal pricing (78%),
clinical guideline development (70%), and clinical practice (59%). Opinions on
whether cost-effectiveness analysis of individualized medicine will become a dom-
inant approach in the next three years varied widely with 49% of respondents in
agreement and 19% disagreeing. Equally, 37% of the respondents agree and 37%
disagree that orphan drugs should be subjected to the same value-based assess-
ments as other products, with 26% being neutral. CONCLUSIONS: While there is
strong agreement that the role of HE data will increase in the areas of pricing,
reimbursement, clinical guideline development and clinical practice, there re-
mains some disagreement about how specific HE approaches and policies will be
applied in the near future. Further research is warranted to better understand the
use of HE data in market access decision making globally.
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OBJECTIVES: Pharmacovigilance as a part of drug safety surveillance consists in
collecting and analysing adverse effects reports and is intended to evaluate the
safety of medicinal products and to eliminate drugs whose risks outweigh thera-
peutic benefits. The research aims were: to recognize the rules of current pharma-
covigilance practices, to examine their capacity to effectively manage public health
and to propose an improved pharmacovigilance model. METHODS: The rules of
drug safety monitoring in the United States, Canada, the UK and Poland have been
presented, analysed and compared. In order to assess the effectiveness of the
respective national practices, an additional analysis covered reports prepared by
health care professionals, consumers and MAHs, submitted to the responsible
health care agencies (FDA, Health Canada, MHRA and URPL, WMiPB). Based on the
results, an improved pharmacovigilance model was proposed. A case study of
VIOXX® was used to review different pharmacovigilance practices by analysing
reports on this recalled drug, including the incidence and type of adverse effects
reported, principles of pharmacovigilance signal detection and measures, taken by
the agencies. The model was then subject to final evaluation. RESULTS: The anal-
ysed pharmacovigilance practices allowed to collect sufficient data on adverse
effects, but none of the agencies raised any alarm addressing safety issues before
the product was recalled by the manufacturer. CONCLUSIONS: The procedures
underlying pharmacovigilance practices need to be amended by adopting the ideas
proposed in the model, especially in the area of data analysis and signal detection,
for instance: rigorous five-year safety monitoring of new products, especially post-
marketing surveillance; publicly available adverse effects reports collected by the
agencies; publicly available standards of signal detection based on MAHs declara-
tions in SPCs; and including clinical trials’ analysis in standard drug safety moni-
toring.
PHP188
FUNDING THE UNFUNDABLE: THE AUSTRALIAN APPROACH FOR SPECIALTY
PHARMACEUTICALS
Lu CY
Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
OBJECTIVES: Specialty drugs are high-cost drugs for treating complex chronic con-
ditions, such as cancer and autoimmune disorders. Most are biologics, and they
provide highly targeted treatment for which there are few other viable treatment
options, but at prices that are substantially higher than traditional medications.
This study examines how Australia funds specialty pharmaceuticals under its pub-
licly funded, national drug coverage system. METHODS: Review of the literature
and analysis of prescription volume and expenditures (2010-2011). RESULTS: In-
herent in all decisions on coverage of new health technologies is uncertainty, aris-
ing from the absence of complete information about comparative (long-term) ef-
fectiveness, incremental cost-effectiveness, adoption and diffusion, and economic
impact. Uncertainty is more pronounced for specialty drugs due, in part, to their
high cost. In response, Australia created a Complex Authority Required Highly
Specialized Drugs Program under the Pharmaceutical Benefits Scheme to fund and
deliver specialty drugs. This program currently includes 34 drugs (e.g. adalimumab,
etanercept, imatinib). Subsidized access to these drugs is restricted to subsets of
patients who must show evidence of the clinical need (e.g. pathology report to
confirm the diagnosis) and whose condition is inadequately controlled by existing,
less expensive therapies. For continued access to many of these agents, patients
must also demonstrate adequate clinical improvement; clinical outcomes are eval-
uated according to predetermined quantifiable criteria. Because of the availability
of multiple effective agents for a single clinical indication (e.g. rheumatoid arthri-
tis), Australia was the first country to establish an ‘interchangeability rule’ under a
publicly funded system that allowed eligible patients to trial an alternate medicine
without the need to re-qualify against the initial criteria. Analysis is underway to
assess the current status of this program, including uptake and economic impacts.
CONCLUSIONS: Australia has created an innovative funding approach to balance
the benefits, risks, and costs of specialty pharmaceuticals.
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OBJECTIVES: To provide an overview of past and current models and practices in
innovative contracting in Germany, the UK, Sweden, Italy and France. Another aim
was to uncover the experiences of different stakeholders with innovative contract-
ing in Germany and the UK. METHODS: A comprehensive literature search on
innovative contracting from 2008 onwards was performed. Information on the
country involved, drug type, characteristic of the therapeutic area, timeframe,
terms of the agreement and stakeholders involved was extracted. Interviews with
22 stakeholders from Germany (n14) and the UK (n8) were conducted. Stake-
holders included pharmaceutical company staff, payers, medical practitioners,
governmental bodies and academics. RESULTS: The countries showing the highest
activity in the use of innovative contracting were the UK (23 from 60 contracts),
followed by Sweden (15/60) and Italy (10/60). Most schemes were applied to oncol-
ogy drugs (29/60). The most frequently mentioned innovative contract model in the
literature was the Coverage with Evidence Development (CED) scheme (23/60).
From the interviews, it was observed that most stakeholders applied these
schemes mainly to arrange broad market access, and were successful in their
implementation (32%). Where stakeholders avoided innovative contracting
schemes, this was due to their complexity, high administrative burden, and uncer-
tainty of its benefits, particularly for payers. The high administrative burden was
regarded as the greatest pitfall of innovative contracting schemes, being men-
tioned by 45% of the stakeholders. For the future, they prefer the use of simple
rebate schemes. CONCLUSIONS: Innovative contracting provides a valuable tool
for new innovative pharmaceuticals to gain market access whilst keeping the im-
pact on payers’ budgets under control. These schemes have not yet gained wide-
spread acceptance, and stakeholders in the UK and in Germany are suspicious as to
their benefit and their future relevance. Systematic research is needed to allow for
the evaluation of these schemes.
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OBJECTIVES: It would appear that ongoing economic austerity would lend itself to
cost containment in health care through a natural increase in use of pharmaco-
economic strategies in general, and risk-sharing agreements in particular. How-
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